Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors [Urologic Oncology]
Conclusion
TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs with an acceptable safety profile. Given higher rates of favorable response, progression-free survival, and overall survival compared with prior first-line studies, TIP warrants further study in this population.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Feldman, Hu, Dorff, Lim, Patil, Woo, Carousso, Hughes, Sheinfeld, Bains, Daneshmand, Ketchens, Bajorin, Bosl, Quinn, Motzer Tags: Clinical Trials, Chemotherapy Urologic Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Germ Cell Tumors | Hematology | Seminoma | Study | Testicular Cancer | Toxicology | Urology & Nephrology